Bioorthogonal Disruption of Pyroptosis Checkpoint for High-Efficiency Pyroptosis Cancer Therapy

Area of Science:

• Biomedical Engineering
• Cancer Therapy
• Nanotechnology

Background:

• Pyroptosis, an inflammatory programmed cell death, shows therapeutic potential for cancer.
• Autophagy acts as a critical checkpoint and survival mechanism in cancer cells, limiting pyroptosis efficacy.
• Disrupting cancer cell self-protection is key to enhancing pyroptosis-based therapies.

Purpose of the Study:

• To develop a bioorthogonal nanoregulator for inducing pyroptosis and overcoming autophagy-mediated resistance in cancer therapy.
• To investigate the dual role of the nanoregulator in triggering pyroptosis and inhibiting the autophagy checkpoint.

Main Methods:

• Construction of a biomimetic, cancer cell membrane-coated nanoregulator.
• In situ mitochondrial synthesis of photosensitizer PpIX to generate reactive oxygen species (ROS) and induce pyroptosis.
• Palladium-catalyzed bioorthogonal chemistry for in situ generation of an autophagy inhibitor to disrupt the pyroptosis checkpoint.

Main Results:

• The nanoregulator successfully induced pyroptosis by generating mitochondrial ROS.
• In situ generated autophagy inhibitor effectively disrupted the pyroptosis checkpoint, enhancing therapeutic efficacy.
• Biomimetic coating ensured cancer cell specificity, minimizing harm to normal tissues, demonstrating a safe and effective antitumor treatment.

Conclusions:

• This work presents the first strategy to disrupt cancer cells' intrinsic protective mechanisms for enhanced pyroptosis therapy.
• Autophagy plays a crucial regulatory role in pyroptosis therapy, highlighting its significance as a therapeutic target.
• The developed nanoregulator platform offers a promising approach for highly efficient and safe cancer treatment by modulating pyroptosis.